ORIGINAL ARTICLE Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

Ipilimumab 3mg/kg was the first agent to improve survival of pretreated advancedmelanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the efficacy of ipilimumab in an expanded access setting and the range of different tumor response patterns encountered. The durable clinical benefit seen in these patients despite the observed atypical response patterns highlights the necessity for comprehensive clinical decision making